ARS Pharmaceuticals
ARS Pharmaceuticals' revenue fell 5.5% to $84 million in fiscal 2025. Its operating margin was −212.9%, down from −3.5% a year earlier. Free cash flow was −$171 million, against $13 million a year earlier. The diluted share count fell 3.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
ARS Pharmaceuticals lost money in fiscal 2025: a net loss of $171 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 60 | 274 | 228 | 314 | 245 |
| Debt incl. finance leases | 8 | 0 | 0 | 0 | 96 |
| Net debt (negative means net cash) | −52 | −274 | −228 | −314 | −149 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | 0.0x | 0.0x | 0.0x | 0.8x |
| Interest coverage | — | — | — | — | −73.2x |
| Current ratio | 7.4x | 51.0x | 96.9x | 14.3x | 7.3x |
| Quick ratio | 7.4x | 51.0x | 96.9x | 13.8x | 6.5x |
Cash flow
Projections
Project ARS Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought ARS Pharmaceuticals shares on the open market, and 2 insiders sold $283,550, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 12, 2026 | Eric KarasChief Commercial Officer | Sold plan | 25,000 | $10.00 | $250,000 | Form 4 |
| Jun 12, 2026 | Alexander A FitzpatrickChief Legal Officer | Sold plan | 3,355 | $10.00 | $33,550 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 8 | 5 of 8 | 2 of 8 |
| Rule of 40 | −198,234.4% | 297,077.9% | −208.6% |
| Altman Z'' | 102.46 | 7.46 | −1.13 |
| Accruals ratio | 1.9% | −1.9% | −0.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Fail |
| Cash from operations is positive | Fail | Pass | Fail |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | 2 of 8 | 5 of 8 | 2 of 8 |
Compare
Put ARS Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| ARS Pharmaceuticals | FY25 | −5.5% | −212.9% | −203.1% | — | — | 2 | |
| Nurix Therapeutics | FY25 | 54.0% | −340.2% | −313.7% | — | — | — | Compare |
| Arcturus Therapeutics | FY25 | −46.1% | −93.0% | −90.8% | — | — | — | Compare |
| Eton Pharmaceuticals | FY25 | 104.9% | −1.1% | 12.8% | −1.9% | 1.4x | 4 | Compare |
| Siga Technologies | FY25 | −31.8% | 25.1% | 45.6% | 34.8% | −6.4x | 5 | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | — | 6 | 1 | 0 | 89 | 84 |
| Revenue growth | — | — | −76.1% | −97.7% | 297,063.3% | −5.5% |
| Gross profit | — | — | — | 0 | — | — |
| Research and development | 25 | 20 | 18 | 20 | 20 | 13 |
| Operating income | −33 | −20 | −36 | −68 | −3 | −179 |
| Net income | −33 | −20 | −35 | −54 | 8 | −171 |
| Diluted EPS (US$) | −11.33 | −0.70 | −0.87 | −0.57 | 0.08 | −1.74 |
| Diluted shares (millions) | 3 | 29 | 40 | 95 | 102 | 99 |
| Cash flow | ||||||
| Cash from operations | −31 | −18 | −40 | −59 | 14 | −171 |
| Capital expenditure | 1 | 0 | 0 | 0 | 1 | 0 |
| Free cash flow | −32 | −18 | −40 | −59 | 13 | −171 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 3 | 3 | 6 | 9 | 14 | 22 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 387 | 60 | 274 | 228 | 314 | 245 |
| Debt incl. finance leases | — | 8 | 0 | 0 | 0 | 96 |
| Total assets | 395 | 61 | 281 | 233 | 351 | 328 |
| Total liabilities | 12 | 17 | 8 | 2 | 94 | 213 |
| Shareholders' equity | −14 | −31 | 273 | 231 | 257 | 114 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | 100.0% | — | — |
| Operating margin | — | −353.3% | −2,698.8% | −225,066.7% | −3.5% | −212.9% |
| Net margin | — | −367.6% | −2,635.4% | −181,216.7% | 9.0% | −203.2% |
| Free cash flow margin | — | −319.9% | −3,060.6% | −198,136.7% | 14.6% | −203.1% |
| Rule of 40 (growth + FCF margin) | — | — | −3,136.7% | −198,234.4% | 297,077.9% | −208.6% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | — | −28.7% | −21.6% | 3.3% | −92.3% |
| Return on assets | — | −8.9% | −20.2% | −21.1% | 2.7% | −50.5% |
| Net debt to EBITDA | — | — | — | — | — | — |